Clinical trial NCT02542202: Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
Official title: A Pilot Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Renal Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Metastatic Renal Cell Cancer
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2015-09-04
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.


Eligibility criteria: Inclusion Criteria:

* Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)
* Patients must have between 1 to 5 new or recurrent lesions suspicious for metastatic RCC on diagnostic imaging

  * Each extracranial lesion must be =\< 6 cm and amenable to SBRT or surgical excision
  * Patients must have 3 or fewer brain metastases, of size =\< 4 cm

    * Brain metastases must be treated prior to enrollment in the study; the modality of treatment of brain metastases can include surgical resection, whole brain radiotherapy, stereotactic radiosurgery, or any combination of the above
  * Patients who have an intact unresected primary tumor should be considered for radical nephrectomy and primary resection prior to enrollment in the study; if the patient is not eligible for surgical resection, the primary tumor must be amenable to SBRT or request for applications (RFA); generally, this will be defined as a primary tumor \< 10 cm in size or a primary lesion which can be treated to a dose of \>= 8 Gy x 5 without excessive perceived risk of toxicity
* Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial; CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms
* Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month
* Patients may not have had prior bevacizumab, based on case reports of tracheoesophageal fistula in patients treated with bevacizumab and radiotherapy
* Eastern Cooperative Oncology Group (ECOG) performance status =\<2
* Age 18 years or older
* Life expectancy of \>= 3 months
* Patients must have normal organ and marrow function within 30 days of registration, as defined below:

  * Absolute neutrophil count \>= 500/mcL
  * Hemoglobin \>= 8.0 g/dL
  * Platelets \>= 50,000/mcL
  * Total bilirubin within normal institutional limits
  * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 X institutional upper limit of normal if liver metastases are present
* Women of childbearing potential must have a negative pregnancy test within 14 days of registration
* Patients must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients who have had prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy within 1 month of enrollment
* Patients who have had any prior bevacizumab, due to case reports suggesting a possible risk of severe toxicity in combination with radiotherapy
* Patients with radiographic or clinical findings of spinal cord compression or cauda equina syndrome with neurologic deficit thought to be due to malignancy
* Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
* Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose
* Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer
* Severe, active co-morbidity, defined as follows:

  * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration;
  * Transmural myocardial infarction within the last 6 months prior to registration;
  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration;
  * Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease if the liver is involved with metastatic disease;
  * Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count \< 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count \>= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
* Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatment

Primary outcomes:
measure: Number of Participants With Radiation Therapy (RT)-Related Grade >= 4 Toxicity
timeFrame: Up to 1 year
Secondary outcomes:
measure: Treated Lesion Control (LeC)
timeFrame: From the start of treatment to the time of local progression at each treated lesion, assessed up to 1 year
measure: Progression-free Survival
timeFrame: From start of treatment to time of progression, assessed up to 1 year
measure: Toxicity Profile of 5-fraction SBRT Based on Normal Tissue Dosimetric Constraints Based on the Organ Site of Involvement
timeFrame: Up to 1 year
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago Comprehensive Cancer Center
state: Illinois
Study officials:
affiliation: University of Chicago Comprehensive Cancer Center
name: Stanley Liauw
role: PRINCIPAL_INVESTIGATOR
References: